Other News To Note
Tuesday, October 30, 2012
Cellectis SA, of Paris, presented data at the European Society of Gene & Cell Therapy meeting in Versailles, France, showing that it can program cells from the immune system (T cells) to kill cancer cells. Cellectis' approach involves isolating cells from the immune systems of healthy patients and genetically programming them to attack cancer cells in sick patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.